Arcutis Biotherapeutics (ARQT) News
NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ARQT news summary
We found 2 recent headlines mentioning Arcutis Biotherapeutics (ARQT): 1 in the past week and 2 in the past 30 days, most often from GlobeNewswire, Nasdaq. ARQT is making an outsized move today, up 8.53% at $26.58, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical", was published by GlobeNewswire on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Arcutis Biotherapeutics headlines
- Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall ClinicalArcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall ClinicalGlobeNewswire
- Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa StudyMRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.NasdaqMRK, AMRN, ACIU, ARQT